(Q35215808)

7 August 2017

1 reference

title

New insights into the pathophysiology of multiple myeloma (English)

1 reference

7 August 2017

1 reference

Sonja Seidl

1

1 reference

7 August 2017

Hannes Kaufmann

series ordinal

2

1 reference

7 August 2017

Johannes Drach

series ordinal

3

1 reference

7 August 2017

publication date

1 September 2003

1 reference

Lancet Oncology Commission

7 August 2017

published in

1 reference

7 August 2017

volume

4

1 reference

7 August 2017

issue

9

1 reference

7 August 2017

page(s)

557-564

1 reference

Plasma cells: finding new light at the end of B cell development

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Multiple myeloma: almost all patients are cytogenetically abnormal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Hypodiploidy is a major prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hé

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Delineation of the minimal region of loss at 13q14 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

A molecular study of the t(4;14) in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Moving disease biology from the lab to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

RANK ligand and osteoprotegerin in myeloma bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

A molecular compendium of genes expressed in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901195-1

7 January 2021

10.1016/S1470-2045(03)01195-1

Identifiers

DOI

1 reference

7 August 2017

1 reference